Risk factors for early recurrence after discontinuing lithium in bipolar disorder

Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. Methods We compared factors for association with recurrences of BD within 12 months o...

Full description

Saved in:
Bibliographic Details
Published inBipolar disorders Vol. 24; no. 7; pp. 720 - 725
Main Authors Baldessarini, Ross J., Pinna, Marco, Contu, Martina, Vázquez, Gustavo H., Tondo, Leonardo
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.11.2022
Subjects
Online AccessGet full text
ISSN1398-5647
1399-5618
1399-5618
DOI10.1111/bdi.13206

Cover

Abstract Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. Methods We compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration. Results Among 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration. Conclusions Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure.
AbstractList Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.BACKGROUNDTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.We compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration.METHODSWe compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration.Among 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration.RESULTSAmong 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration.Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure.CONCLUSIONSEarly recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure.
Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. Methods We compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration. Results Among 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration. Conclusions Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure.
BackgroundTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.MethodsWe compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration.ResultsAmong 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration.ConclusionsEarly recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure.
Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. We compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration. Among 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration. Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure.
Author Tondo, Leonardo
Contu, Martina
Vázquez, Gustavo H.
Baldessarini, Ross J.
Pinna, Marco
Author_xml – sequence: 1
  givenname: Ross J.
  orcidid: 0000-0001-9718-8211
  surname: Baldessarini
  fullname: Baldessarini, Ross J.
  email: rbaldessarini@mclen.harvard.edu
  organization: Harvard Medical School
– sequence: 2
  givenname: Marco
  surname: Pinna
  fullname: Pinna, Marco
  organization: Cagliari & Rome
– sequence: 3
  givenname: Martina
  surname: Contu
  fullname: Contu, Martina
  organization: Cagliari & Rome
– sequence: 4
  givenname: Gustavo H.
  surname: Vázquez
  fullname: Vázquez, Gustavo H.
  organization: Queen's University School of Medicine
– sequence: 5
  givenname: Leonardo
  surname: Tondo
  fullname: Tondo, Leonardo
  organization: Cagliari & Rome
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35319801$$D View this record in MEDLINE/PubMed
BookMark eNp1kUlLBDEQhYMo7gf_gAS86GE0Sy_J0V1BEEXPIZNUNNqTjEk3Mv_eODNeROtSdfjeo3hvC62GGAChPUqOaZmTsfXHlDPSrKBNyqUc1Q0Vq_NblLtqN9BWzm-E0IaReh1t8JpTKQjdRA-PPr9jp00fU8YuJgw6dTOcwAwpQTCAteshYeuziaH3YfDhBXe-f_XDBPuAx34aOz0HYrKQdtCa012G3eXeRs9Xl0_nN6O7--vb89O7kWGCNyNteNtUhGgKFCwIKaUmjRVjZmshuWS2tdowDk3Na9caLpxwxgnGmZCkdXwbHS58pyl-DJB7NSkvQtfpAHHIijVVYduKVAU9-IW-xSGF8p1iLRdc1JLxQu0vqWE8AaumyU90mqmfsApwsgBMijkncMr4Xve-xJK07xQl6rsOVepQ8zqK4uiX4sf0L3bp_uk7mP0PqrOL24XiC41tmAY
CitedBy_id crossref_primary_10_3390_su15054128
crossref_primary_10_2174_2666082219666221228123312
crossref_primary_10_7759_cureus_43604
crossref_primary_10_1177_02698811231166460
crossref_primary_10_1186_s40345_024_00339_6
Cites_doi 10.1176/ajp.154.4.551
10.1111/bdi.12105
10.1176/appi.ajp.2007.06101639
10.1176/appi.ajp.2010.09060880
10.1159/000506868
10.1176/appi.ajp.2018.17091001
10.1001/archpsyc.1997.01830130055011
10.1017/S0033291720004778
10.1001/archpsyc.1993.01820180046005
10.1177/2045125314540297
10.1159/000497334
10.1111/bdi.13017
10.1111/j.1399-5618.2007.00389.x
ContentType Journal Article
Copyright 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright © 2022 John Wiley & Sons A/S
Copyright_xml – notice: 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
– notice: Copyright © 2022 John Wiley & Sons A/S
DBID AAYXX
CITATION
NPM
7TK
7X8
DOI 10.1111/bdi.13206
DatabaseName CrossRef
PubMed
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Neurosciences Abstracts
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-5618
EndPage 725
ExternalDocumentID 35319801
10_1111_bdi_13206
BDI13206
Genre article
Journal Article
GrantInformation_xml – fundername: Bruce J Anderson Foundation
  funderid: 2021‐22
– fundername: Aretaeus Foundation of Rome
– fundername: McLean Private Donors Psychiatric Research Fund
– fundername: Bruce J Anderson Foundation
  grantid: 2021-22
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OC
23N
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
NPM
7TK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
7X8
ID FETCH-LOGICAL-c2836-ac376400a1e1ede8999a06d8b2d589392d7dac23e6535f7c38f8fcf82328907f3
IEDL.DBID DR2
ISSN 1398-5647
1399-5618
IngestDate Fri Jul 11 15:07:38 EDT 2025
Fri Jul 25 21:06:28 EDT 2025
Wed Feb 19 02:25:56 EST 2025
Thu Apr 24 23:01:24 EDT 2025
Tue Jul 01 04:32:31 EDT 2025
Wed Jan 22 16:26:49 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords recurrence
lithium treatment
bipolar disorder
risk factors
discontinuation
Language English
License 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2836-ac376400a1e1ede8999a06d8b2d589392d7dac23e6535f7c38f8fcf82328907f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9718-8211
PMID 35319801
PQID 2738385923
PQPubID 2045186
PageCount 6
ParticipantIDs proquest_miscellaneous_2642327404
proquest_journals_2738385923
pubmed_primary_35319801
crossref_citationtrail_10_1111_bdi_13206
crossref_primary_10_1111_bdi_13206
wiley_primary_10_1111_bdi_13206_BDI13206
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2022
PublicationDateYYYYMMDD 2022-11-01
PublicationDate_xml – month: 11
  year: 2022
  text: November 2022
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Hoboken
PublicationTitle Bipolar disorders
PublicationTitleAlternate Bipolar Disord
PublicationYear 2022
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2018; 175
2013; 15
2014; 4
2021; 23
1993; 50
1997; 54
2019; 88
2021
1997; 154
2010; 167
2007; 164
2007; 9
2020; 89
e_1_2_9_11_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_12_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_14_1
References_xml – volume: 54
  start-page: 49
  year: 1997
  end-page: 55
  article-title: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
  publication-title: Arch Gen Psychiatry
– volume: 9
  start-page: 435
  year: 2007
  end-page: 442
  article-title: Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study
  publication-title: Bipolar Disord
– volume: 164
  start-page: 1817
  year: 2007
  end-page: 1824
  article-title: Recurrences of bipolar disorder in pregnancy: prospective study of mood‐stabilizer discontinuation
  publication-title: Am J Psychiatry
– volume: 50
  start-page: 448
  year: 1993
  end-page: 455
  article-title: Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders
  publication-title: Arch Gen Psychiatry
– volume: 88
  start-page: 65
  year: 2019
  end-page: 70
  article-title: Effects of treatment discontinuation in clinical psychopharmacology
  publication-title: Psychother Psychosom
– volume: 89
  start-page: 283
  year: 2020
  end-page: 306
  article-title: Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications
  publication-title: Psychother Psychosom
– volume: 4
  start-page: 198
  year: 2014
  end-page: 219
  article-title: Role of long‐acting injectable antipsychotics in schizophrenia: a critical appraisal
  publication-title: Ther Adv Psychopharmacol
– volume: 175
  start-page: 765
  year: 2018
  end-page: 773
  article-title: 20‐year nation‐wide follow‐up study on discontinuation of antipsychotic treatment in first‐episode schizophrenia
  publication-title: Am J Psychiatry
– year: 2021
  article-title: Twenty‐year effects of antipsychotics in schizophrenia and affective psychotic disorders
  publication-title: Psychol Med
– volume: 23
  start-page: 14
  year: 2021
  end-page: 23
  article-title: Prevention of suicidal behavior in bipolar disorder
  publication-title: Bipolar Disord
– volume: 154
  start-page: 551
  year: 1997
  end-page: 553
  article-title: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study
  publication-title: Am J Psychiatry
– volume: 167
  start-page: 934
  year: 2010
  end-page: 941
  article-title: Discontinuation rate vs. recurrence risk following long‐term antidepressant treatment in major depressive disorder patients
  publication-title: Am J Psychiatry
– volume: 15
  start-page: 645
  year: 2013
  end-page: 649
  article-title: Effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation‐induced refractoriness
  publication-title: Bipolar Disord
– ident: e_1_2_9_8_1
  doi: 10.1176/ajp.154.4.551
– ident: e_1_2_9_13_1
  doi: 10.1111/bdi.12105
– ident: e_1_2_9_6_1
  doi: 10.1176/appi.ajp.2007.06101639
– ident: e_1_2_9_10_1
  doi: 10.1176/appi.ajp.2010.09060880
– ident: e_1_2_9_2_1
  doi: 10.1159/000506868
– ident: e_1_2_9_11_1
  doi: 10.1176/appi.ajp.2018.17091001
– ident: e_1_2_9_9_1
  doi: 10.1001/archpsyc.1997.01830130055011
– ident: e_1_2_9_12_1
  doi: 10.1017/S0033291720004778
– ident: e_1_2_9_7_1
  doi: 10.1001/archpsyc.1993.01820180046005
– ident: e_1_2_9_14_1
  doi: 10.1177/2045125314540297
– ident: e_1_2_9_4_1
  doi: 10.1159/000497334
– ident: e_1_2_9_5_1
  doi: 10.1111/bdi.13017
– ident: e_1_2_9_3_1
  doi: 10.1111/j.1399-5618.2007.00389.x
SSID ssj0016205
Score 2.401979
Snippet Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with...
Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk...
BackgroundTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 720
SubjectTerms Bipolar disorder
Diagnosis
discontinuation
Latency
Lithium
lithium treatment
Morbidity
recurrence
Risk factors
Survival analysis
Title Risk factors for early recurrence after discontinuing lithium in bipolar disorder
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbdi.13206
https://www.ncbi.nlm.nih.gov/pubmed/35319801
https://www.proquest.com/docview/2738385923
https://www.proquest.com/docview/2642327404
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB5VPay4LMtjoWwXGcRhL6maOHFccdqlVAUJJCoq9YAU-RVt1CWt2ubCr2fGeYjCIiFukTKRHdsz843t-QbgzThXCGodD4RRNkAPFQaKCx0YqXlkJTp05W9bfBbzZfxxlax68LbNhan5IboNN9IMb69JwZXe_6Lk2hYjyv8luu2QC-LNny466qhQRP76IgIcGSQiThtWIbrF03157Iv-AJjHeNU7nNlD-NZ2tb5nsh5VBz0yP35jcfzPfzmD0waIsut65TyCnisfw8mn5qj9CXxZFPs1a8rxMIS2zBEXMtvRBr1PEWS-vjijvN4N1Zuo0AsyRPW3RfWdFSXTxZbiZhLwBJ9PYTl7__XdPGjqLwQGQYcIlEHrgzquQhc66zAyw4kTVurIJghzJpFNrTIRdyLhSZ4aLnOZm1wiSJMYc-f8HPrlpnTPgcnUmFTqSTiRYaxjPdFoKbUZhzY2-diZAVy1M5GZhpycamTcZW2QgkOU-SEawOtOdFszctwnNGynM2uUcp9RFhKXCULaAbzqXqM60RmJKt2mQhlBJ9dpPI4H8KxeBl0rnOwVenTsrJ_Mvzef3Uw_-IcX_y56AQ8iSq3weY5D6B92lbtEwHPQL_3K_glgW_o-
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-QwDLZ4SAsXYBcWhtdmVxy4dDRt2jQjceGp4SktAokLqppHtRXQQTC98Oux04dgAQlxq1RXSePY_hzHNsBGL0sR1FruCZ0aDy2U76VcKE9LxQMj0aCn7rbFmRhchkdX0dUYbDW5MFV9iPbAjSTD6WsScDqQfiHlyuRdSgAW4zDp4nMEic7b4lG-CNwFRoQ40otEGNd1hegeT_vpa2v0BmK-RqzO5BzMwnUz2eqmyU23HKmufvqvjuNX_2YOZmosyrarzfMdxmzxA76d1tH2efh7nj_esLojD0N0yyyVQ2YPdEbvsgSZazHOKLV3SC0nSjSEDIH9v7y8Y3nBVH5PrjMRuBqfC3B5sH-xO_DqFgyeRtwhvFSjAkIxT33rW2PROUPeCSNVYCJEOv3AxCbVAbci4lEWay4zmelMIk6T6HZn_CdMFMPCLgGTsdaxVH2_L_1QhaqvUFkq3fNNqLOe1R3YbFiR6Lo-ObXJuE0aPwWXKHFL1IE_Lel9VZTjPaLVhp9JLZePCSUicRkhqu3A7_Y1ShSFSdLCDkukERS8jsNe2IHFah-0o3BSWWjUcbKOmx8Pn-zsHbqH5c-T_oKpwcXpSXJyeHa8AtMBZVq4tMdVmBg9lHYN8c9Irbtt_gwKT_5c
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkFAvUKCFpVswiAOXrDZx4njVU1tYsUARIJA4VIriR0QEZFewufTXM-M8VB6VELdImciOxzPzjT0PgJ1-liKotdwTOjUeWijfS7lQnpaKB0aiQU9dtMWJOLgMD6-iqxn43uTCVPUh2gM3kgynr0nAJyb7R8iVyXuU_ys-wFwo0EwSIjpva0f5InDxi4hwpBeJMK7LClEYT_vpU2P0AmE-BazO4gwX4U8z1yrQ5KZXTlVP_31WxvGdP_MJFmokyn5UW2cJZmyxDPO_67v2FTg7zx9uWN2PhyG2ZZaKIbN7OqF3OYLMNRhnlNg7poYTJZpBhrD-Oi_vWF4wlU_IcSYCV-HzM1wO9y9-HXh1AwZPI-oQXqpR_aCQp771rbHomiHnhJEqMBHinEFgYpPqgFsR8SiLNZeZzHQmEaVJdLoz_gVmi3Fh14DJWOtYqoE_kH6oQjVQqCqV7vsm1Fnf6g7sNpxIdF2dnJpk3CaNl4JLlLgl6sB2SzqpSnK8RtRt2JnUUvmQUBoSlxFi2g5sta9RnuiSJC3suEQaQVfXcdgPO7BabYN2FE4KC006TtYx8__DJz_3Ru5h_e2kmzB_ujdMjkcnR1_hY0BpFi7nsQuz0_vSfkPwM1UbbpM_AhIh_Qs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+early+recurrence+after+discontinuing+lithium+in+bipolar+disorder&rft.jtitle=Bipolar+disorders&rft.au=Baldessarini%2C+Ross+J&rft.au=Pinna%2C+Marco&rft.au=Contu%2C+Martina&rft.au=V%C3%A1zquez%2C+Gustavo+H&rft.date=2022-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1398-5647&rft.eissn=1399-5618&rft.volume=24&rft.issue=7&rft.spage=720&rft.epage=725&rft_id=info:doi/10.1111%2Fbdi.13206&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1398-5647&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1398-5647&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1398-5647&client=summon